

First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults

NCT07205926

Status	RECRUITING
Phase	Phase 1
Sponsor	Inventprise Inc.
Enrollment	60 participants

Key Eligibility Criteria

Inclusion (9)

- Participants who meet all the following criteria may be included in the study:
- Age 18 to 49 years at the time of Dose 1
- Good general health status, as determined by medical history, physical examination, safety laboratory tests, ECG, vital signs, and clinical judgment
- BMI e 18.0 kg/m² and d 32.0 kg/m²
- Negative alcohol breath test and urine drug screen results at Screening and on Day 1
- ... and 4 more (see full listing online)

Exclusion (28)

- Participants who meet any of the following criteria will be excluded from the study:
- Currently lactating
- History of shigellosis or participation in a Shigella challenge study
- History of bloody diarrhea without alternative diagnosis
- History of inflammatory bowel disease
- ... and 23 more (see full listing online)

Locations (1 total)

Medpace Clinical Pharmacology Unit, Cincinnati, Ohio, United States